Document is current
Any future updates will be listed below
-
Authors
Vidal-Taboada, José M. https://orcid.org/0000-0001-5667-4133
Pugliese, Marco https://orcid.org/0000-0001-7499-4667
Salvadó, Maria https://orcid.org/0000-0002-1526-1903
Gámez, Josep https://orcid.org/0000-0002-0426-1844
Mahy, Nicole https://orcid.org/0000-0002-4733-4951
Rodríguez, Manuel J. https://orcid.org/0000-0002-4476-004X
-
Funding
Funding for this research was provided by:
Agència de Gestió d’Ajuts Universitaris i de Recerca (2014SGR1115)
Comissió Interdepartamental de Recerca i Innovació Tecnològica (RD10-1-0072)
Ministerio de Sanidad, Servicios Sociales e Igualdad (FIS-FEDER PI16-01673)
Ministerio de Sanidad, Servicios Sociales e Igualdad (FIS-FEDER PI 17-00789)
Secretaría de Estado de Investigación, Desarrollo e Innovación (SAF2007-88076-R)
- License Information
-
More Information
Article History
Received: 29 September 2017
Accepted: 16 February 2018
First Online: 28 February 2018
Compliance with Ethical Standards
: The local IRBs at the Vall d’Hebron Research Institute, the DIBAPS Biobank, and the Spanish National DNA Bank approved the protocols of this study. It was conducted according to the principles set out in the Declaration of Helsinki. All patients and/or close relatives gave their written informed consent to participation in the study in paper format, and a blood sample for genetic analysis was obtained from all of them. CNS tissue donors gave their informed written consent for the use of CNS tissue for research purposes. The categorization of ALS patients was performed according to their clinical features (familial or sporadic ALS forms, bulbar or spinal or respiratory onset, rate of progression, and survival time). No experiments with animals were performed in this study.
: MP, NM, and MJR applied for a PCT application “Diazoxide for use in the treatment of amyotrophic lateral sclerosis (ALS)” (Application number PCT/EP2011/064061). The other authors declare that they have no conflict of interest.
